Results For "Bristol-Myers-Squibb"

93 News Found

Biocon settles suit with Celgene for generic Revlimid

Biotech | September 08, 2021

Biocon settles suit with Celgene for generic Revlimid

Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020

Syngene Q1 FY22 revenue grows 41%

News | July 21, 2021

Syngene Q1 FY22 revenue grows 41%

The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels

Sun Pharma settles patent litigation for Revlimid

News | June 23, 2021

Sun Pharma settles patent litigation for Revlimid

Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules

Latest Stories

Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings

Trelegy Ellipta gets green light in China for adults with uncontrolled asthma

Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging